Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to reopen collapsed lungs in ventilator patients

NCT ID NCT07451405

Disease control Sponsor: Capital Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new therapy called oscillation and lung expansion (OLE) in 60 adults on ventilators who have collapsed lungs (atelectasis). OLE combines continuous pressure, high-frequency vibrations, and medication mist to clear mucus and reopen lung tissue. Researchers will compare it to standard chest wall vibration therapy using CT scans and electrical impedance tomography to see which works better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Oscillation and lung expansion (OLE) therapy
What this could lead to
If successful, this could provide a more effective and comfortable way to treat lung collapse in patients on ventilators, potentially reducing complications.
What could go wrong
This is a small, early-stage trial with only 60 participants, so results may not apply to all patients. The therapy may not work better than current methods and could cause discomfort or injury.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years old * The following characteristics of high mucus secretion in the airway occur along with pulmonary infection: coughing up a large amount of white sticky phlegm, yellow phlegm or yellow purulent phlegm; Phlegm sounds can be heard in the lungs. The frequency of sputum aspiration is higher than once every 4 hours * Tracheotomy time ≥7 days * Vital signs are stable. Exclusion Criteria: * Hemodynamic instability * Inhaled oxygen concentration (FiO2) \> 60% * Untreated pneumothorax * Patients who have undergone total pneumonectomy * Hemoptysis * Pulmonary bullae, etc. * Patients with delirium and restlessness

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atelectasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

middle lobe syndrome Pulmonary Atelectasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atelectasis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Respiratory rehabilitation center

    RECRUITING

    Beijing, Beijing Municipality, 100144, China

  • Shuo Chen

    COMPLETED

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.